Yüklüyor......
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
BACKGROUND: Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). METHODS: Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles...
Kaydedildi:
| Yayımlandı: | Cephalalgia |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959035/ https://ncbi.nlm.nih.gov/pubmed/27288354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102416652092 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|